Retatrutide: Why the "Next Big" Weight-Loss Shot Has Scientists So Excited
Five big trials, some of the biggest weight-loss results ever reported, and an FDA filing planned for early 2027. Here's why retatrutide is earning the hype, and how to get ready for it the safe way.
Someone in your group chat calls it "reta." Your feed calls it the next big thing. For once, the hype may actually be earned.
Retatrutide has now been tested in five large, late-stage trials, and every one of them hit its main goal. The weight loss is some of the biggest ever reported for a weight-loss medicine. Here's what makes it special, what the studies found, and how to be ready for it the safe way.
What Makes Retatrutide Different
Retatrutide is a peptide, a short chain of building blocks your body already knows how to read (see Article 10). It's a once-a-week shot made by Eli Lilly, the company behind Zepbound.
What sets it apart is how many hormone "switches" it flips:
- Semaglutide (Wegovy) works on one: GLP-1.
- Tirzepatide (Zepbound) works on two: GLP-1 and GIP.
- Retatrutide works on three: GLP-1, GIP, and glucagon.
GLP-1 and GIP help you feel full sooner and handle sugar better. Glucagon is the new piece: researchers think it helps your body burn more energy, including fat stored in the liver. One molecule, three jobs. That's why scientists call it a "triple agonist," and why they're so excited.
The Results, Trial by Trial
- The first big test (2023): in a mid-stage trial, people on the highest dose lost an average of 24% of their body weight in 48 weeks.
- Knee arthritis (December 2025): adults with obesity and painful knees lost an average of 28.7% on the top dose over 68 weeks, and their knee pain dropped by up to 76%.
- The main obesity trial (May 2026): in 2,339 adults, the top dose led to an average loss of 28.3% at 80 weeks. Nearly half (45%) lost 30% or more, a level once seen only with weight-loss surgery. In an extension for people who started at a higher weight, those who kept going lost an average of 30.3% by two years.
- Type 2 diabetes (July 2026): up to 20.8% average weight loss, plus a big drop in blood sugar (A1C down as much as 1.6 points).
- Heart disease (July 2026): up to 22.6% average weight loss in adults with severe obesity and heart disease.
For comparison, in their own main trials, semaglutide averaged about 15% and tirzepatide about 21%. Retatrutide's top dose went well past both.
And one detail moms may love: the lowest dose, reached with just one step up, still averaged about 19%. In that trial, people on it were no more likely to stop because of side effects than people on the placebo.
It's Not Just About the Scale
The numbers that excite doctors most aren't always the pounds. In the trials, retatrutide also:
- Shrank waistlines by up to 9.5 inches on average
- Lowered blood pressure, triglycerides, and cholesterol
- Cut a key marker of inflammation (hsCRP) roughly in half
- Eased knee arthritis pain and improved how people moved
Lilly is also studying it for sleep apnea, fatty liver disease, back pain, and heart and kidney health. Those results are still to come.
The Honest Part: Side Effects
Strong medicine comes with real side effects, and the trials were open about them:
- Stomach trouble is the big one. On the top dose in the main trial, about 42% had nausea, about a third had diarrhea, and about a quarter had constipation or vomiting. These are the same kinds of side effects people get with Wegovy and Zepbound, and they're why the dose goes up slowly.
- A tingly or sensitive-skin feeling (doctors call it dysesthesia) showed up in about 1 in 8 people on the higher doses, compared with about 1 in 100 on placebo. It was mostly mild and usually went away.
- A faster heartbeat was seen in the 2023 trial. It rose in the first months and then eased.
- Some people stopped. On the top dose, about 11% quit because of side effects, compared with about 5% on placebo.
- Not for pregnancy or breastfeeding. There's no safety data yet, so if you're pregnant, trying to get pregnant, or nursing, this one isn't for you right now.
How to Get Ready, the Safe Way
- Talk to your doctor about approved options now. Wegovy, Zepbound, and others are available today, and they work. Our guide to GLP-1s after baby walks you through them.
- Look into a trial. Search "retatrutide" at ClinicalTrials.gov. Right now, a trial is the only legal way to take it.
- Protect your muscle. Big weight loss can take muscle with it. Strength work and enough protein help (see Strength for Real Life).
- Bring these questions to your next visit: Am I a good fit for an approved weight-loss medicine right now? Would I qualify for a retatrutide trial? How would these medicines fit with birth control, breastfeeding, or plans for another baby? How do I protect my muscle while I lose weight?
Not sure where to start? Take our 60-second quiz and get the reads that fit your season.
The Bottom Line
Retatrutide may be the most exciting weight-loss medicine yet: five big trials, results in a range once seen only with surgery, and real gains for blood pressure, blood sugar, and joints. Lilly plans to ask the FDA for approval in early 2027, and if it's approved, it could change a lot of lives. Maybe yours.
The smart move is to be ready, not early. Start the conversation with your doctor today, so when retatrutide is approved, you're first in line for the real thing.
This article is education, not medical advice. Retatrutide is an investigational medicine and is not FDA-approved. Talk to your doctor before starting, stopping, or changing any medicine.
The Series
30 articlesSources & references (8)
- Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." New England Journal of Medicine, 2023 — New England Journal of Medicine, 2023
- Eli Lilly and Company. TRIUMPH-4 Phase 3 topline results, December 11, 2025 — Eli Lilly and Company, 2025
- Eli Lilly and Company. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (TRIUMPH-1 topline results), May 21, 2026 — Eli Lilly and Company, 2026
- U.S. FDA. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." — U.S. Food and Drug Administration
- ClinicalTrials.gov: retatrutide studies — ClinicalTrials.gov (NIH)
- Eli Lilly and Company. "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (press release stating a planned Q1 2027 FDA submission), July 23, 2026 — Eli Lilly and Company, 2026
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021 — New England Journal of Medicine, 2021
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022 — New England Journal of Medicine, 2022
This article is education, not medical advice. If you're struggling, call or text 988, or call Postpartum Support International at 1-800-944-4773.
Find your weight starting point
Five quick questions, and we'll pick the articles and emails that fit where you are.
- Your mom type, and what it says about you
- Three articles picked for your answers
- Emails that fit your life, not everyone's
How old is your youngest?
Free · about 60 seconds. Your results come by email right away, then a short email every few days, then the Sunday Letter. Unsubscribe anytime.
More in The Series
Selank and Semax, the Russian "Brain Peptides": What Moms Should Know
October 12, 2026 · Here's what Selank and Semax are, what the small Russian studies and a 2026 FDA review really found, and what helps a racing, foggy mom brain right now.
NAD+, the "Energy Molecule": What Moms Should Know
October 12, 2026 · What NAD+ really is (hint: not a peptide), what the human studies actually tested, and what helps when you're tired all the time.
DSIP, the "Deep Sleep" Peptide: What Moms Should Know
October 12, 2026 · Here's what DSIP is, what the small, decades-old studies on sleep really found, and what actually helps when you're running on broken nights.
Discussion
Loading comments…